Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies

被引：552

作者：

Byun, David J. ^{[1
,2
]}

Wolchok, Jedd D. ^{[1
,2
]}

Rosenberg, Lynne M. ^{[2
]}

Girotra, Monica ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

[2] Weill Cornell Med Coll, 1300 York Ave, New York, NY 10065 USA

来源：

NATURE REVIEWS ENDOCRINOLOGY | 2017年 / 13卷 / 04期

关键词：

CELL LUNG-CANCER; T-LYMPHOCYTE ANTIGEN-4; LONG-TERM SAFETY; HYPOPHYSITIS CLINICAL PRESENTATION; IPILIMUMAB-INDUCED HYPOPHYSITIS; AUTOIMMUNE THYROID-DISEASE; PHASE-II TRIAL; ADVANCED MELANOMA; METASTATIC MELANOMA; ADVERSE EVENTS;

D O I：

10.1038/nrendo.2016.205

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Advances in cancer therapy in the past few years include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) are two co-inhibitory receptors that are expressed on activated T cells against which therapeutic blocking antibodies have reached routine clinical use. Immune checkpoint blockade can induce inflammatory adverse effects, termed immune-related adverse events (IRAEs), which resemble autoimmune disease. In this Review, we describe the current data regarding immune-related endocrinopathies, including hypophysitis, thyroid dysfunction and diabetes mellitus. We discuss the clinical management of these endocrinopathies within the context of our current understanding of the mechanisms of IRAEs.

引用

页码：195 / 207

页数：13

共 135 条

[1]

Agabegi S. S., 2013, STEP UP TO MED

[2] Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].

Agata, Y ;

Kawasaki, A ;

Nishimura, H ;

Ishida, Y ;

Tsubata, T ;

Yagita, H ;

Honjo, T .

INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772

[3] Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma [J].

Albarel, Frederique ;

Gaudy, Caroline ;

Castinetti, Frederic ;

Carre, Tiphaine ;

Morange, Isabelle ;

Conte-Devolx, Bernard ;

Grob, Jean-Jacrues ;

Brue, Thierry .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (02) :195-204

[4]

Amin A, 2009, J CLIN ONCOL, V27

[5]

[Anonymous], 2012, YERVOY

[6] Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].

Ansell, Stephen M. ;

Hurvitz, Sara A. ;

Koenig, Patricia A. ;

LaPlant, Betsy R. ;

Kabat, Brian F. ;

Fernando, Donna ;

Habermann, Thomas M. ;

Inwards, David J. ;

Verma, Meena ;

Yamada, Reiko ;

Erlichman, Charles ;

Lowy, Israel ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453

[7] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].

Antonia, Scott ;

Goldberg, Sarah B. ;

Balmanoukian, Ani ;

Chaft, Jamie E. ;

Sanborn, Rachel E. ;

Gupta, Ashok ;

Narwal, Rajesh ;

Steele, Keith ;

Gu, Yu ;

Karakunnel, Joyson J. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2016, 17 (03) :299-308

[8] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[9] Ipilimumab-Induced Adrenalitis A Possible Pitfall in 18F-FDG-PET/CT [J].

Bacanovic, Sara ;

Burger, Irene A. ;

Stolzmann, Paul ;

Hafner, Juerg ;

Huellner, Martin W. .

CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) :e518-e519

[10] Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? [J].

Bednarczuk, Tomasz ;

Gopinath, Bamini ;

Ploski, Rafal ;

Wall, Jack R. .

CLINICAL ENDOCRINOLOGY, 2007, 67 (01) :3-19

← 1 2 3 4 5 6 7 8 9 10 →